Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410630 · ClinicalTrials.gov registry record
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- 66
- Enrollment target
NCT01410630 is a clinical trial that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 66 participants.
The verdict
NCT01410630 has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
Study Summary
A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that yields better tracking of cancer treatment progress. PET/CT stands for positron emission tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT uses a new tracer, fluorothymidine, which is taken up by cells that are actively proliferating or dividing such as cancer cells. We hope to learn whether this tracer is superior to the conventional tracer for monitoring treatment of diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG FLT
- DIAGNOSTIC_TEST FLT-PET/CT
- DIAGNOSTIC_TEST FDG-PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2019-10-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01410630
The ClinicalTrials.gov registry entry for NCT01410630 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FLT is the first listed.
NCT01410630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01410630 about?
NCT01410630 is a clinical study titled "FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma". A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that yields better tracking of cancer treatment progress. PET/CT stands for positron emission tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT uses a new tracer, fluorot...
What is the current status of trial NCT01410630?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2017-09-07. Estimated completion is 2019-10-04.
What interventions are being tested in trial NCT01410630?
The interventions under investigation include: FLT (DRUG), FLT-PET/CT (DIAGNOSTIC_TEST), FDG-PET/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01410630?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.